Sickle Cell Disease Assoc. Of America On FDA Approval Of Gene Therapies
On Dec. 8, 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for sickle cell disease (SCD), Casgevy from CRISPR/Vertex and Lyfgenia from bluebird bio. Become a Harlem Insider! Sign-Up for our Newsletter *Select list(s) to subscribe toHarlem World Magazine Example: Yes, I would like to receive emails from Harlem World Magazine.…